MedTrace Logo

Choroideremia Gene Therapy Clinical Trial

NCT02553135 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2019-07-29

Study results available
· View outcomes & findings →

Summary

Phase II gene therapy study, involving a total of 6 male patients with choroideremia. The study will be conducted at the Bascom Palmer Eye Institute, University of Miami. Patients will be required to attend a total of 11 study visits over a 24 month period with an additional 3 year follow-up.

Conditions

  • Choroideremia

Interventions

BIOLOGICAL

Injection of AAV2-REP1 (10e11 vg)

Single Group: single arm study

Sponsors & Collaborators

  • Byron Lam

    lead OTHER

Principal Investigators

  • BYRON LAM, MD · UNIVERSITY OF MIAMI, BASCOM PALMER EYE INSTITUTE

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2018-02-28
Completion
2018-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02553135 on ClinicalTrials.gov